Universität zu Köln

Chyla, Brenda, Stilgenbauer, Stephan, Eichhorst, Barbara, Schetelig, Johannes, Munir, Talha, Hillmen, Peter, Seymour, John F., Roberts, Andrew W., Coutre, Steven, Jurczak, Wojciech, Mulligan, Stephen P., Puvvada, Soham, Wendtner, Clemens, Davids, Matthew S., Boettcher, Sebastian, Cerri, Elisa, Zhou, Lang, Popovic, Relja, Poteracki, Mia, Arzt, Jennifer, Kim, Su Young, Verdugo, Maria, Bhathena, Anahita, Wierda, William and Hallek, Michael (2017). Venetoclax in relapsed/refractory chronic lymphocytic leukemia (CLL) with 17p deletion: outcome and minimal residual disease from the full population of the pivotal M13-982 trial. Leuk. Lymphoma, 58. S. 234 - 236. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Stilgenbauer, Stephan, Eichhorst, Barbara, Schetelig, Johannes, Hillmen, Peter, Seymour, John F., Coutre, Steven, Jurczak, Wojciech ORCID: 0000-0003-1879-8084, Mulligan, Stephen P., Schuh, Anna, Assouline, Sarit, Wendtner, Clemens-Martin, Roberts, Andrew W., Davids, Matthew S., Bloehdorn, Johannes, Munir, Talha, Boettcher, Sebastian, Zhou, Lang, Salem, Ahmed Hamed, Desai, Monali, Chyla, Brenda, Arzt, Jennifer, Kim, Su Young, Verdugo, Maria, Gordon, Gary, Hallek, Michael and Wierda, William G. (2018). Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. J. Clin. Oncol., 36 (19). S. 1973 - 1984. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Wierda, William, Chyla, Brenda, Eichhorst, Barbara, Schetelig, Johannes, Munir, Talha, Hillmen, Peter, Seymour, John F., Roberts, Andrew W., Coutre, Steven, Jurczak, Wojciech, Mulligan, Stephen P., Wendtner, Clemens-Martin, Davids, Matthew, Boettcher, Sebastian, Cerri, Elisa, Zhou, Lang, Popovic, Relja, Poteracki, Mia, Arzt, Jennifer, Kim, Su Young, Verdugo, Maria, Bhathena, Anahita, Stilgenbauer, Stephan and Hallek, Michael (2017). Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) with 17p Deletion: Outcome and Minimal Residual Disease (MRD) from the Full Population of the Pivotal M13-982 Trial. Clin. Lymphoma Myeloma Leuk., 17. S. S303 - 1. DALLAS: CIG MEDIA GROUP, LP. ISSN 2152-2669